Affimed (A28A) Q3 2024 Earnings Report

The earnings call highlighted significant progress in clinical trials, particularly with AFM24 and AFM28, and a strategic focus on partnerships and financial health. However, there were notable challenges, including a decline in revenue and reduced cash reserves. Despite these challenges, the company's efforts to improve its financial position and strategic focus are promising.

During the Affimed Q3 2024 earnings call, significant financial and operational metrics were presented, highlighting the company's progress and future expectations. Affimed reported a cash balance of EUR 24.1 million at the end of Q3 2024, down from EUR 72 million at the end of 2023, indicating a reduction due to operational activities. The net cash used in operating activities was EUR 11.1 million for Q3 2024 compared to EUR 18.3 million in Q3 2023, reflecting improved operational efficiency. Total revenue for the quarter was EUR 0.2 million, a decrease from EUR 2 million in the same period last year, while R&D expenses were reduced to EUR 10.1 million from EUR 21.5 million in Q3 2023. Affimed also reported a net loss of EUR 15.1 million, improving from a net loss of EUR 24.4 million in Q3 2023. The company anticipates that its current financial resources, including expected proceeds from the ATM program and the sale of AbCheck, will fund operations into the fourth quarter of 2025. These metrics underscore Affimed's strategic focus on financial health and operational efficiency as it advances its clinical programs and seeks potential partnerships.